MedTrace Logo

Probiotic in Patients With Bile Acid Malabsorption/Diarrhea

NCT06609148 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.

Conditions

  • Bile Acid Malabsorption
  • Bile Acid Diarrhea

Interventions

DIETARY_SUPPLEMENT

De Simone formulation probiotic

Subjects will be given De Simone formulation probiotic 900 billion CFU, 3 times per day for 21-24 days

DIETARY_SUPPLEMENT

Placebo

Subjects will be given a placebo for 21-24 days

Sponsors & Collaborators

Principal Investigators

  • Michael Camilleri, MD, DSc · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-02
Primary Completion
2026-03-31
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06609148 on ClinicalTrials.gov